An observational study in Diffuse Large B Cell Lymphoma, Large B-cell Lymphoma and Primary Mediastinal Large B Cell Lymphoma, sponsored by Pell Bio-Med Technology Co., Ltd.. Recruiting at 5 sites in Taiwan. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Pell Bio-Med Technology Co., Ltd. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Lymphoma, Large B-Cell, Diffuse with a site in Taiwan — 5 open to participants now, 19 under way, 10 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Taiwan.
Among the 37 studies in Lymphoma, Large B-Cell, Diffuse with a site in Taiwan, this one is one of 5 that started in 2023, is one of 3 observational ones, reaches primary completion later than 18 of the 18 other live ones, and was the 29th registered.
1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →5 of the 37 studies in Lymphoma, Large B-Cell, Diffuse with a site in Taiwan are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in Taiwan, United States, Argentina and 32 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Taiwan, United States, Australia and 20 more countries
Ages 6 mo–25 yrs
AstraZeneca · Sites in Taiwan, United States, Brazil and 2 more countries
Ages 65–99
Regeneron Pharmaceuticals · Sites in Taiwan, United States, Australia and 18 more countries
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 8 · Phase 3 19
First in 1996; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 49 is below the median of 150 across 186 observational studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 359 across the 34 interventional studies, 49 across the 3 observational. Of the 18 that completed or were terminated, 8 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 37 have an industry lead sponsor. The 10 most frequent:
Pell Bio-Med Technology Co., Ltd. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Pell Bio-Med Technology Co., Ltd. has 2 studies filed under Lymphoma, Large B-Cell, Diffuse — fewer than ten, so there is no comparison to draw.
4 of the studies in Lymphoma, Large B-Cell, Diffuse with a site in Taiwan that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
| NCT05578976Phase 3GenmabA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | 2027-06 |
| NCT05326243Pell Bio-Med Technology Co., Ltd.Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma | 2026-12-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 37 studies in Lymphoma, Large B-Cell, Diffuse with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
According to health authorities guidances (FDA 2006, EMA(European Medicines Agency) 2009) for gene therapy clinical trials, observing subjects for delayed adverse events for 15 years is recommended. This purpose of this long-term follow-up study is to evaluate the safety and efficacy in patients who have ever received lentiviral-based gene-edited immune cells which are manufactured by Pell Bio-Med Technology Co. Ltd.
After completion or early withdraw from the other treatment protocol, patients should be enrolled into this long-term follow-up study. If patients do not enter this study right after leaving the treatment protocol, they may have the option to enter this long-term follow-up study at any time within 15 years after the last lentiviral-based gene-edited immune cell infusion.
The study population includes all patients who have ever received Pell's lentiviral-based gene-edited immune cell therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
There are no specific exclusion criteria for this study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After completion or early withdraw from the treatment protocol, patients will be enrolled into this long-term follow-up study. If patients do not enter this study right after leaving the treatment protocol, they may have the option to enter this study at any time within 15 years after the last lentiviral-based gene-edited immune cell infusion.
Genetic: Pell's lentiviral-based gene-edited immune cell therapy
Some patients may require joining other Pell's gene-edited immune cell therapy study during participating in this long-term follow-up study. For such case, the patient could be enrolled into the new treatment protocol. Meanwhile, the patient can be remaining in this long-term follow-up protocol as an inactive participant.
Genetic: Pell's lentiviral-based gene-edited immune cell therapy
No study drug or other planned treatment will be administered. Subjects who previously received Pell's lentiviral-based gene-edited immune cell therapy will be evaluated the safety and efficacy.
To assess delayed adverse events which are suspected related to previous gene-edited immune cell therapy
• Proportion of patients with any events of the following items which are suspected related to previous gene-edited immune cell therapy. 1. New malignancies 2. New incidence or exacerbation of a pre-existing neurologic disorder 3. New incidence or exacerbation of a prior rheumatologic or other autoimmune disorder 4. New incidence of a hematologic disorder, including hypogammaglobulinemia 5. New incidence of infection (potentially product-related) 6. Other than the above adverse events, which are suspected related to gene-edited immune cell therapy judged by the investigator
Time frame: 15 years
Monitor for Replication Competent of Lentivirus (RCL)
Proportion of patients with detectable RCL in peripheral blood by VSV-G(Vesicular stomatitis virus G) qPCR
Time frame: 15 years
Monitor the persistence of gene-edited immune cells in peripheral blood(By qPCR)
Proportion of patients with detectable transgene level in peripheral blood by qPCR
Time frame: 15 years
Monitor the persistence of gene-edited immune cells in peripheral blood(By Flowcytometry)
Persistence of gene-edited immune cells in peripheral blood using flow cytometry
Time frame: 5 years
To assess the long-term efficacy of gene-edited immune cells
1. Proportion of patients with relapse or progress among patients who didn't progress or relapse at study entry/reentry 2. Incidence of death
Time frame: 15 years
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Dec 2036, 165 months after the start.
Of 66 observational studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 114. This study's planned 165 months is above that.
Start moved once since we started tracking on Sep 25, 2026: Dec 2022 → Mar 2023, on Oct 9, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lymphoma, Large B-Cell, Diffuse →
Pell Bio-Med Technology Co., Ltd.